[Future perspectives and strategies in managing resistance to analogue antiviral drugs in the treatment of chronic hepatitis B].
Bourlière
Marc
M
Service d'hépato-gastroentérologie, Hôpital Saint Joseph, 26 bd de Louvain, 13008 Marseille, France. stanislas.pol@nck.ap-hop-paris.fr
D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D024882:Drug Resistance, Viral / Q000235:genetics; D004359:Drug Therapy, Combination; D005544:Forecasting; D017325:Hepatitis B Vaccines / Q000008:administration & dosage; D006515:Hepatitis B virus / Q000187:drug effects* / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D009154:Mutation / Q000187:drug effects; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
D000998:Antiviral Agents; D017325:Hepatitis B Vaccines; D016898:Interferon-alpha; D018894:Reverse Transcriptase Inhibitors